Results 211 to 220 of about 1,682,340 (366)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Codon bias shapes bacterial small RNA binding sites within protein-coding sequences. [PDF]

RNA
Fisher S, Margalit H.
europepmc   +1 more source

Evolutionary computation for discovery of composite transcription factor binding sites

, 2008
Gary B. Fogel, V William Porto, Gábor Varga, Ernst R. Dow, Andrew M. Craven, David Powers, Harry B. Harlow, Ee Wern Su, J.E. Onyia, Su Chen   +9 more
openalex   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Cardiac glycoside binding sites in cultured heart muscle cells [PDF]

, 1984
Erdmann, E., B. Zwißler, W. Krawietz, E. Erdmann, B. Wagenknecht, Wagenknecht, B., Werdan, K., Zwißler, Bernhard, K. Werdan, Krawietz, W.   +9 more
core   +1 more source

Toxic shock syndrome toxin-1のマウスリンパ球上のbinding site の研究

, 1988
竹彦 内山, 小傑 巌, 健一 今西, 慎二 斎藤   +3 more
openalex   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

A DNABERT based deep learning framework for predicting transcription factor binding sites. [PDF]

Sci Rep
Dutta P, Ghosh N, Santoni D.
europepmc   +1 more source

Aminoacyl-tRNA binding at the recognition site is the first step of the elongation cycle of protein synthesis.

, 1977
James A. Lake
openalex   +2 more sources